STOCKS TELEGRAPH

Tag: Aadi Bioscience

  • Aadi Bioscience Surges in Afterhours Trading Following Clinical Results

    Aadi Bioscience, Inc. (NASDAQ: AADI) experienced a significant surge in after-hours trading on Friday, jumping an impressive 58.10%. This spike follows a respectable 2.4% climb during regular trading hours earlier in the day. The heightened interest in AADI is expected to carry over the weekend and potentially reflect in Monday’s trading.

    Aadi Bioscience is a commercial-stage biopharmaceutical company focused on developing precision therapies for cancer. Their primary focus is on cancers with alterations in the mTOR pathway, a crucial regulator of cell growth and cancer progression.

    Aadi has already achieved FDA approval and commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

    Recent Clinical Study Results

    The recent surge in interest seems to be tied to the publication of long-term efficacy and safety results from Aadi’s Phase 2 registrational AMPECT study of nab-sirolimus in malignant PEComa, while the study, published in the Journal of Clinical Oncology (JCO), showed promising outcomes.

    Dr. Andrew J. Wagner, Senior Physician at the Dana-Farber Cancer Institute, commented on the study’s results, noting that responses to nab-sirolimus in patients with advanced PEComa lasted a median of 39.7 months, with a confirmed overall response rate of 38.7%.

    Investor Interest and Future Prospects

    Investors are attracted to Aadi Bioscience due to the positive clinical trial results and the company’s active shelf. Despite PEComa being a small market, there is speculation that Aadi’s therapies could extend to other indications, potentially increasing its market reach.

    With a median survival of 53 months even in metastatic cases and a large cash position, some believe that Aadi Bioscience is undervalued at its current price of $2 per share.

    Conclusion

    Aadi Bioscience’s recent surge in afterhours trading reflects growing investor interest following the publication of positive long-term clinical trial results.

    The company’s focus on precision therapies for cancer, particularly in the mTOR pathway, shows promise for future growth and expansion into other indications. As Aadi continues to advance its therapies and explore new clinical programs, it remains a company to watch in the biopharmaceutical industry.

  • Aerpio Pharmaceuticals, Inc. (ARPO) Stock Surges After Being Massively Upgraded by Analysts

    Aerpio Pharmaceuticals, Inc. (ARPO) Stock Surges After Being Massively Upgraded by Analysts

    Aerpio Pharmaceuticals, Inc. (ARPO) stock prices skyrocketed by 69.0059% some time after market trading commenced on July 8th, 2021, bringing the price per share up to USD$2.89 earlier in the trading day.

    Upgrading of ARPO Stock

    Analyst Robert Burns of H.C Wainwright upgraded ARPO from a Neutral rating to a Buy, with the company’s stock being given a USD$22 price target. Burns cited the transformative nature of the merger as being the driving force behind the upgrading of the company. Furthermore, the merger is expected to facilitate the transition to a self-sustaining, commercial-stage enterprise, with a distinguished flagship product that boasts applicability across a myriad of oncology indications.

    Merger with Aadi Bioscience

    May 16th, 2021 saw the company announce its strategic merger with Aadi Bioscience, Inc. and Aspen Merger Subsidiary, Inc. The agreement will see Aadi surviving the merger as a wholly-owned subsidiary of ARPO, with both companies’ Board of Directors having given their approval. Following the merger, ARPO will continue as Aadi Bioscience and will focus on the development of FYARRO.

    PIPE Financing

    In connection to the merger, ARPO entered into subscription agreements to raise up to USD$155 million in Private Investment in Public Equity (PIPE) financing. The PIPE will see shares of the company’s common stock and pre-funded warrants being used to purchase Aerpio’s common stock. This move is expected to be executed at the same time as the closing of the merger, as per customary closing conditions and the closing of the merger itself.

    Solid Liquidity Position

    March 31st, 2021 saw the company report USD$39 million in cash and cash equivalents, down from the USD$42.6 million reported as of December 31st, 2020. ARPO reported a total of almost 47.4 million common shares outstanding as of March 31st, 2021, with weighted average common shares, both basic and diluted, outstanding totaling 47.3 million as of the end of the quarter.

    R&D Expenses

    The first quarter of fiscal 2021, ended March 31st, 2021, saw ARPO report USD$2.2 million in research and development costs, up 21.8% from the USD$1.8 million reported for the three-month period ended March 31st, 2020. This year-over-year difference was largely driven by increased expenses associated with the company’s clinical programs.

    Net Loss Reports

    Net loss attributable to common stockholders was USD$4.4 million for the quarter ended March 31st 2021, representing a net loss of USD$0.09 per common share. This is comparable to the USD$3.9 million in net loss reported for Q1 2020, which came out to a net loss of USD$0.10 per common share.

    Future Outlook for ARPO

    Armed with the massive scope in light of its recent merger, ARPO is poised to capitalize on the expanded opportunities afforded to it. The company is keen to leverage its combined resources to usher in sustained and organic growth over the long term. With a target price of USD$22.00, investors are snowballing the growth as it climbs higher and higher towards that goal.